Two siblings with genetically confirmed cartilage-hair hypoplasia responded very differently to recombinant human growth hormone treatment.
Patient 1 gained 1.04 standard deviation scores in height during treatment, while his sister Patient 2 gained only 0.39 standard deviation scores. Both children carried compound heterozygous variants in the RMRP gene.
The brother started treatment at 4.1 years of age and continued for 3.5 years. His sister began at 3.5 years of age and received the therapy for 1.75 years.
Sequencing at the Manchester Centre for Genomic Medicine found the same variants in trans, corresponding to n.72A>G and n.238A>G in current nomenclature.
Patient 1 had two subnormal growth hormone stimulation peaks, recording 4.7 micrograms per liter with glucagon and 2.8 micrograms per liter with arginine. Patient 2 recorded a single borderline peak of 9.1 micrograms per liter using a glucagon stimulation test.
Both children presented with severe short stature before starting the off-label therapy in the United Kingdom. Their treatments were later monitored after the family moved to Portugal.
Patient 1 developed severe obesity with a body mass index standard deviation score of +4.98 and a homeostasis model assessment of insulin resistance score of 3.4. Patient 2 recorded a body mass index standard deviation score of +2.27 and an insulin resistance score of 7.2.
Both patients exhibited T-cell lymphopenia with low CD4+ counts. Patient 1 experienced no severe infections, whereas Patient 2 developed varicella encephalitis with sepsis at 15 months of age.
The condition results from biallelic variants in the RMRP gene, which encodes the RNA component of mitochondrial RNA-processing endoribonuclease. Both parents were confirmed as carriers in the United Kingdom.
Patient 1 had two clearly subnormal stimulation tests, while Patient 2 had a single borderline result.
Manchester Centre for Genomic Medicine was launched on 20 May 2013 as a partnership between The University of Manchester and Central Manchester University Hospitals NHS Trust. The Centre brings together the NHS Genetic Medicine Service and the University’s Department of Genetic Medicine in an integrated research and diagnostic environment.
Since 2010, Manchester-based researchers have discovered more than 15 genes causing serious developmental problems in children, blindness, deafness and inherited cancers, more breakthroughs than any other comparable centre in the UK.
The collaboration involves over 250 researchers, doctors, genetic counsellors, nurses and diagnostic scientists. Its Genetics Service sees 12,000 patients annually from across the North of England and carries out 20,000 diagnostic tests per year. The Centre also leads international organisations linking 1,300 laboratories in more than 60 countries to ensure the quality and accuracy of genetic tests.
Neither child experienced a malignancy or direct treatment-related adverse effect during the documented follow-up period. Both developed insulin resistance and vitamin D deficiency over time.
Worth a look